A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

20191,580 citationsJournal Articlegreen Open Access

Authors

Sabué Mulangu · Alliance for International Medical Action

Lori E. Dodd · National Institutes of Health

Richard T. Davey · National Institutes of Health

Olivier Tshiani Mbaya · Alliance for International Medical Action

Michael A. Proschan · National Institutes of Health

Daniel Mukadi‐Bamuleka · Alliance for International Medical Action

Mariano Lusakibanza Manzo

Abstract

Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD. Scientifically and ethically sound clinical research can be conducted during disease outbreaks and can help inform the outbreak response. (Funded by the National Institute of Allergy and Infectious Diseases and others; PALM ClinicalTrials.gov number, NCT03719586.).

Topics & Keywords

Viral Infections and Outbreaks Research Viral Infections and Vectors Disaster Response and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 24, pp. 2293-2303

DOI: 10.1056/nejmoa1910993

Field-Weighted Citation Impact: 169.89